Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The Panc cancer results are very good!

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon May 20, 2021 12:22pm

171 Views

Post# 33238003

RE:RE:RE:The Panc cancer results are very good!

Don't forget. pembrolizumab alone also play an important role in the treatment. That's why it is called modest rather than "very promising".

JohnnyYeg wrote: Are you serious Actuarial??? "don't know if modest efficacy is good"?? For a death sentence like pancreatic cancer, honestly tell me modest efficacy isn't good. SMH.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec